J. J. Grantham, Autosomal dominant polycystic kidney disease, N Engl J Med, vol.359, pp.1477-1485, 2008.

V. E. Torres, P. C. Harris, and Y. Pirson, Autosomal dominant polycystic kidney disease, Lancet, vol.369, pp.1287-1300, 2007.
URL : https://hal.archives-ouvertes.fr/hal-01785829

D. Bichet, D. Peters, and A. J. Patel, Cardiovascular polycystins: insights from autosomal dominant polycystic kidney disease and transgenic animal models, Trends Cardiovasc Med, vol.16, pp.292-298, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00113523

T. Ecder, Cardiovascular complications in autosomal-dominant polycystic kidney disease, Curr Hypertens Res, vol.9, pp.2-11, 2013.

A. Patel and E. Honoré, Polycystins and renovascular mechanosensory transduction, Nat Rev Nephrol, vol.6, pp.530-538, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00727665

S. M. Nauli, Y. Kawanabe, and J. J. Kaminski, Endothelial cilia are fluid shear sensors that regulate calcium signaling and nitric oxide production through polycystin-1, Circulation, vol.117, pp.1161-1171, 2008.

W. A. Aboualaiwi, M. Takahashi, and B. R. Mell, Ciliary polycystin-2 is a mechanosensitive calcium channel involved in nitric oxide signaling cascades, Circ Res, vol.104, pp.860-869, 2009.

O. Kocaman, H. Oflaz, and E. Yekeler, Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease, Am J Kidney Dis, vol.43, pp.854-860, 2004.

P. Clausen, B. Feldt-rasmussen, and J. Iversen, Flow-associated dilatory capacity of the brachial artery is intact in early autosomal dominant polycystic kidney disease, Am J Nephrol, vol.26, pp.335-339, 2006.

I. Kocyigit, M. I. Yilmaz, and O. Orscelik, Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease, Nephron Clin Pract, vol.123, pp.157-164, 2013.

S. Abdul-majeed and S. M. Nauli, Dopamine receptor type 5 in the primary cilia has dual chemo-and mechano-sensory roles, Hypertension, vol.58, pp.325-331, 2011.

J. N. Barendregt, K. W. Florijn, and Y. Muizert, Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion, Nephrol Dial Transplant, vol.10, pp.1332-1341, 1995.

M. P. Audrézet, C. Gall, E. Chen, and J. M. , Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients, Hum Mutat, vol.33, pp.1239-1250, 2012.

J. Bellien, A. Costentin, and B. Dutheil-maillochaud, Early stage detection of conduit artery endothelial dysfunction in patients with type 1 diabetes, Diab Vasc Dis Res, vol.7, pp.158-166, 2010.

R. Joannides, A. Costentin, and M. Iacob, Influence of vascular dimension on gender difference in flow-dependent dilatation of peripheral conduit arteries, Am J Physiol Heart Circ Physiol, vol.282, pp.1262-1269, 2002.

J. Bellien, M. Iacob, and R. , Epoxyeicosatrienoic acids contribute with altered NO and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension, Circulation, vol.125, pp.1266-1275, 2012.

S. Namli, H. Oflaz, and F. Turgut, Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease, Ren Fail, vol.29, pp.55-59, 2007.

V. Menon, D. Rudym, and P. Chandra, Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease, Clin J Am Soc Nephrol, vol.6, pp.7-13, 2011.

M. Merta, J. Reiterová, and R. Rysavá, Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease, Physiol Res, vol.52, pp.433-437, 2003.

D. Wang, O. Braendstrup, and S. Larsen, The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats, APMIS, vol.112, pp.358-368, 2004.

D. Wang, J. Iversen, and C. S. Wilcox, Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease, Kidney Int, vol.64, pp.1381-1388, 2003.

M. A. Al-nimri, R. Komers, and T. T. Oyama, Endothelial-derived vasoactive mediators in polycystic kidney disease, Kidney Int, vol.63, pp.1776-1784, 2003.

J. Bellien, R. Joannides, and V. Richard, Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?, Pharmacol Ther, vol.131, pp.1-17, 2011.

J. Bellien, M. Iacob, and L. Gutierrez, Crucial role of NO and endotheliumderived hyperpolarizing factor in human sustained conduit artery flowmediated dilatation, Hypertension, vol.48, pp.1088-1094, 2006.

C. Gall, E. Audrézet, M. P. Chen, and J. M. , Type of PKD1 mutation influences renal outcome in ADPKD, J Am Soc Nephrol, vol.24, pp.1006-1013, 2013.

F. Turgut, H. Oflaz, and S. Namli, Ambulatory blood pressure and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease, Ren Fail, vol.29, pp.979-984, 2007.

R. Joannides, W. Haefeli, and L. Linder, Nitric oxide is responsible for flowdependent dilation of human peripheral conduit arteries in vivo, Circulation, vol.91, pp.1314-1319, 1995.

I. Fleming, Molecular mechanisms underlying the activation of eNOS, Pflugers Arch, vol.459, pp.793-806, 2010.

G. V. Desir and A. J. Peixoto, Renalase in hypertension and kidney disease, Nephrol Dial Transplant, vol.29, pp.22-28, 2014.

Y. Pei, J. Obaji, and A. Dupuis, Unified criteria for ultrasonographic diagnosis of ADPKD, J Am Soc Nephrol, vol.20, pp.205-212, 2009.

A. D. Hughes, S. A. Thom, and N. M. Woodall, Dopamine produces forearm vasodilatation following alpha-adrenoceptor blockade by an action on vascular dopamine (DA1) receptors in man, J Hypertens, vol.5, pp.337-340, 1987.

I. Os, S. E. Kjeldsen, and A. Westheim, Endocrine and haemodynamic responses to graded dopamine infusion in essential hypertension

, Scand J Clin Lab Invest, vol.47, pp.371-377, 1987.